약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 4.

Table. 4.

Causal inference approach of the association of statin use with cirrhosis and hepatocellular carcinoma according to statin dose

Outcome Statin dose (N) Superlearning TMLE

Marginal OR 95% CI
Cirrhosis Cumulative dose
cDDD<30 (37,118) 1 (Ref)
30≤cDDD<180 (4,627) 0.67* 0.58-0.76
180≤cDDD<720 (5,371) 0.56** 0.47-0.65
720≤cDDD (5,029) 0.51** 0.42-0.60
Yearly dose
cDDD<10 (37,118) 1 (Ref) 0.69-0.89
10≤cDDD<30 (3,450) 0.64** 0.56-0.71
30≤cDDD<120 (6,044 ) 0.58** 0.51-0.65
120≤cDDD (2,284) 0.62** 0.54-0.70
Statin classification
Hydrophilic statin (16,401) 0.56** 0.50-0.62
Lipophilic statin (4,569) 0.69** 0.56-0.81
Hepatocellular carcinoma Cumulative dose
cDDD<30 (37,118) 1 (Ref) 0.94-1.06
30≤cDDD<180 (4,627) 0.61** 0.51-0.72
180≤cDDD<720 (5,371) 0.59* 0.48-0.69
720≤cDDD (5,029) 0.52** 0.42-0.63
Yearly dose
cDDD<10 (37,118) 1 (Ref)
10≤cDDD<30 (3,450) 0.62** 0.53-0.72
30≤cDDD<120 (6,044 ) 0.56** 0.47-0.64
120≤cDDD (2,284) 0.61** 0.51-0.72
Statin classification
Hydrophilic statin (16,401) 0.56** 0.47-0.63
Lipophilic statin (4,569) 0.70** 0.57-0.83

Marginal odds ratio for causal inference from targeted maximum likelihood estimation (TMLE) with adjustment for dyslipidemia, cardiovascular disease, high blood pressure, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

* p<0.05, ** p<0.01

Yakhak Hoeji 2024;68:44-55 https://doi.org/10.17480/psk.2024.68.1.44
© 2024 Yakhak Hoeji